Harrow Health, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for HROW, updated each market day.
HROW AI Sentiment
AI predicts Harrow Health, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Harrow Health, Inc. Common Stock
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Sector
Exchange
Market Cap
$1,388,295,699
Cap Tier
Employees
373
Headquarters
NASHVILLE, TN
Listed Since
April 30, 2007
Website
HROW Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
HROW Volatility
Harrow Health, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
